Localization of active forms of C-jun kinase (JNK) and p38 kinase in Alzheimer's disease brains at different stages of neurofibrillary degeneration
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
The principal protein component of paired helical filaments (PHFs) in Alzheimer disease is abnormally hyperphosphorylated tau (PHF-tau). The stress activated protein kinases JNK and p38 have been shown to phosphorylate tau at some sites only seen in PHF-tau. If JNK and p38 are involved in the abnormal hyperphosphorylation of tau, they should be activated in neurons undergoing neurofibrillary degeneration. In the present study, we determined the intracellular and regional distribution of the active forms of JNK and p38 kinase in entorhinal, hippocampal, and temporal cortices of brains staged for neurofibrillary changes according to Braak and Braak. Neurons with tangle-like inclusions positive for active forms of JNK and p38 kinase were found to appear first in the Pre-alpha layer of the entorhinal cortex, and then extend into other brain regions co-incident with the progressive sequence of neurofibrillary changes. The intraneuronal accumulation of active forms of JNK and p38 kinase apeared to precede the deposition of amyloid in the extracellular space. These data indicate that increased activation of the stress related kinases JNK and p38 occurs very early in the disease and might be involved in the intraneuronal protein phosphorylation/dephosphorylation imbalance that leads to neurofibrillary degeneration in Alzheimer disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Increased p38MAPK activity has been reported in AD brains and lymphocytes [205,206,207,208], as well as in the cortex of a mouse model of AD [209].”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [208]
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Self-citationGrundke-Iqbal, I., Iqbal, K., Tung, Y. C., Quinlan, M., Wisniewski, H. M., & Binder, L. I. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.13.4913 · Cited by 3,676
Self-citationBoulton, T. G., Nye, S. H., Robbins, D. J., Ip, N. Y., Radzlejewska, E., Morgenbesser, S. D., DePinho, R. A., Panayotatos, N., Cobb, M. H., & Yancopoulos, G. D. (1991) · Cell · doi:10.1016/0092-8674(91)90098-j · Cited by 1,897 · cited 1×
“These serine/threonine protein kinases are activated in response to a variety of extracellular stimuli and mediate signal transduction from the cell surface to the nucleus [ 4 ,10].”
BackgroundMicrotubule-associated protein tau. A component of Alzheimer paired helical filaments.
Grundke-Iqbal, I., Iqbal, K., Quinlan, M., Tung, Y. C., Zaidi, M. S., & Wisniewski, H. M. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)38495-8 · Cited by 1,778 · cited 1×
“…Bengt Winblada and Richard F. Cowburna aSection for Geriatric Medicine, NEUROTEC, Karolinska Institutet, Novum, KFC, S-141 86 Huddinge, Sweden bDepartment of Anatomy, J.W. Goethe University, Frankfurt, Germany cNYS Institute for Basic Research in Developmental Disabilities, Staten Island, NY,…”
BackgroundSelf-citationConversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration
Patrick, G. N., Zukerberg, L., Nikolic, M., de la Monte, S., Dikkes, P., & Tsai, L.-H. (1999) · Nature · doi:10.1038/45159 · Cited by 1,545 · cited 1×
“The intraneuronal accumulation of active forms of JNK and p38 kinase apeared to precede the deposition of amyloid in the extracellular space.”
BackgroundBancher, C., Brunner, C., Lassmann, H., Budka, H., Jellinger, K., Wiche, G., Seitelberger, F., Grundke-Iqbal, I., Iqbal, K., & Wisniewski, H. M. (1989) · Brain Research · doi:10.1016/0006-8993(89)91396-6 · Cited by 818
Self-citationBraak, F., Braak, H., & Mandelkow, E. M. (1994) · Acta Neuropathologica · doi:10.1007/bf00293315 · Cited by 772
Self-citationPhosphoprotein Phosphatase Activities in Alzheimer Disease Brain
Gong, C., Singh, T. J., Grundke‐Iqbal, I., & Iqbal, K. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb03603.x · Cited by 527 · cited 1×
“Keywords: Alzheimer’s disease, JNK, p38 kinase, neurofibrillary tangles”
Self-citationPei, J.-J., Braak, E., Braak, H., Grundke-Iqbal, I., Iqbal, K., Winblad, B., & Cowburn, R. F. (1999) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199909000-00011 · Cited by 459 · cited 2×
“If JNK and p38 are involved in the abnormal hyperphosphorylation of tau, they should be activated in neurons undergoing neurofibrillary degeneration.”
BackgroundSelf-citationVincent, I., Jicha, G., Rosado, M., & Dickson, D. W. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-10-03588.1997 · Cited by 444 · cited 2×
“This type of immunostaining which has also been found to be preferentially associated with active but not with inactive GSK-3 [26], active MAP kinase [27,28], cdc2 [34], cdk5 [24,36] and PKA [19] is reminiscent of classical NFTs, as visualized by silver impregnation, or by immunocytochemistry with mAbs Tau-1 or AT8 [2…”
Background
Cited by
Stefani, M., & Dobson, C. M. (2003) · Journal of Molecular Medicine · doi:10.1007/s00109-003-0464-5 · Cited by 1,651
Tau pathology in Alzheimer disease and other tauopathies
Iqbal, K., del C. Alonso, A., Chen, S., Chohan, M. O., El-Akkad, E., Gong, C.-X., Khatoon, S., Li, B., Liu, F., Rahman, A., et al. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2004.09.008 · Cited by 1,037
“The MAP kinase family, which includes ERK1, ERK2, p70S6 kinase and the stress-activated kinases JNK and p38 kinase, have been shown to phosphorylate tau at several of the same sites as the abnormally hyperphosphorylated tau and so has been the association of these enzymes with the progression of neurofibrillary degene…”
BackgroundSelf-citationTau and neurodegenerative disease: the story so far
Iqbal, K., Liu, F., & Gong, C.-X. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.225 · Cited by 806
Self-citationMechanisms of tau-induced neurodegeneration
Iqbal, K., Liu, F., Gong, C.-X., Alonso, A. D. C., & Grundke-Iqbal, I. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0486-3 · Cited by 628
“The MAP kinase family, which includes ERK1, ERK2, p70S6 kinase and the stress-activated kinases JNK and p38 kinase, have been shown to phosphorylate tau at several of the same sites as the abnormally hyperphosphorylated tau and so has been the association of these enzymes with the progression of neurofibrillary degene…”
Self-citationTargeting JNK for therapeutic benefit: from junk to gold?
Manning, A. M., & Davis, R. J. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1132 · Cited by 585
“JNKs 1, 2 and 3 distributed to different subcellular structures specific to the Alzheimer's disease brai”
BackgroundAgeing, Cellular Senescence and Neurodegenerative Disease
Kritsilis, M., V. Rizou, S., Koutsoudaki, P. N., Evangelou, K., Gorgoulis, V. G., & Papadopoulos, D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102937 · Cited by 448
Alzheimer's disease: the two-hit hypothesis
Zhu, X., Raina, A. K., Perry, G., & Smith, M. A. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00707-0 · Cited by 426
Oxidative stress signalling in Alzheimer's disease
Zhu, X., Raina, A. K., Lee, H.-G., Casadesus, G., Smith, M. A., & Perry, G. (2004) · Brain Research · doi:10.1016/j.brainres.2004.01.012 · Cited by 390
Targeting p38 MAPK pathway for the treatment of Alzheimer's disease
Munoz, L., & Ammit, A. J. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.11.010 · Cited by 369
“Several groups using human post-mortem tissues from control and Alzheimer's cases confirmed the observations that in human AD brains the p38 MAPK activation occurs at the very early stage (Pei et al., 2001; Sun et al., 2003).”
BackgroundOxidative Stress Signaling in Alzheimers Disease
Su, B., Wang, X., Nunomura, A., Moreira, P., Lee, H.-G., Perry, G., Smith, M., & Zhu, X. (2008) · Current Alzheimer Research · doi:10.2174/156720508786898451 · Cited by 344
“JNK/SAPK activation apparently precedes amyloid deposition [87,91,92], and it is also interesting to note that the nuclear localization of active JNK/SAPK is almost uniformly detected in most susceptible neurons in early AD stages, a pattern that is similar to the oxidative marker 8OHG, suggesting that oxidative stres…”
ResultFang, F., Lue, L.-F., Yan, S., Xu, H., Luddy, J. S., Chen, D., Walker, D. G., Stern, D. M., Yan, S., Schmidt, A. M., et al. (2010) · The FASEB Journal · doi:10.1096/fj.09-139634 · Cited by 335
Green, K. N., Martinez-Coria, H., Khashwji, H., Hall, E. B., Yurko-Mauro, K. A., Ellis, L., & LaFerla, F. M. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.0055-07.2007 · Cited by 325
“JNK has been shown to hyperphosphorylate tau (Reynolds et al., 1997; Yoshida et al., 2004; Tatebayashi et al., 2006) and is found in tau-laden neurons in AD (Pei et al., 2001; Zhu et al., 2001).”
BackgroundLi, X., Alafuzoff, I., Soininen, H., Winblad, B., & Pei, J. (2005) · The FEBS Journal · doi:10.1111/j.1742-4658.2005.04833.x · Cited by 324
Self-citationLee, J. K., & Kim, N.-J. (2017) · Molecules · doi:10.3390/molecules22081287 · Cited by 320
“In the human AD brain, p38 MAPK activation occurs in the early stage, as confirmed by studies using human post-mortem tissues from control and Alzheimer’s cases [6,55].”
BackgroundAn, W.-L., Cowburn, R. F., Li, L., Braak, H., Alafuzoff, I., Iqbal, K., Iqbal, I.-G., Winblad, B., & Pei, J.-J. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63687-5 · Cited by 312
Self-citationFerrer, I., Gomez-Isla, T., Puig, B., Freixes, M., Ribe, E., Dalfo, E., & Avila, J. (2005) · Current Alzheimer Research · doi:10.2174/1567205052772713 · Cited by 304
Oxidative Stress in Neurodegeneration
Shukla, V., Mishra, S. K., & Pant, H. C. (2011) · Advances in Pharmacological Sciences · doi:10.1155/2011/572634 · Cited by 288
“of Cdk5 and p38 is observed [139, 140].”
Giraldo, E., Lloret, A., Fuchsberger, T., & Viña, J. (2014) · Redox Biology · doi:10.1016/j.redox.2014.03.002 · Cited by 268
Urolithin A attenuates memory impairment and neuroinflammation in APP/PS1 mice
Gong, Z., Huang, J., Xu, B., Ou, Z., Zhang, L., Lin, X., Ye, X., Kong, X., Long, D., Sun, X., et al. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1450-3 · Cited by 254
“Studies have demonstrated that the activation of P38MAPK by Aβ occurred in the postmortem brains of AD patients and animal models, indicating that p38MAPK is involved in the pathogenesis of AD [54].”
Protein phosphorylation in neurodegeneration: friend or foe?
Tenreiro, S., Eckermann, K., & Outeiro, T. F. (2014) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2014.00042 · Cited by 252
“In the course of AD, ERK and JNK are activated throughout all stages, and p38 in mild to severe cases (Braak stages III to VI) (Pei et al., 2001; Zhu et al., 2001). p38 and JNK immunoreactivity were associated with neurons containing neuritic plaques, neuropil threads, and NFTs, structures that…”
BackgroundPei, J.-J., Braak, H., An, W.-L., Winblad, B., Cowburn, R. F., Iqbal, K., & Grundke-Iqbal, I. (2002) · Molecular Brain Research · doi:10.1016/s0169-328x(02)00488-6 · Cited by 247
Self-citationNeuronal cell cycle: the neuron itself and its circumstances
Frade, J. M., & Ovejero-Benito, M. C. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1004937 · Cited by 243
“Moreover, p38 has been linked with AD as well(97) and its active form can be detected in the brain of AD patients from the very early stages of the disease, becoming increased with age.(98,99) In addition, E2F4 can also be detected in the normal brain(100) (Table 1), suggesting that the p75/p38/E2F4 pathway may also p…”
BackgroundInvolvement of p38 MAPK in Synaptic Function and Dysfunction
Falcicchia, C., Tozzi, F., Arancio, O., Watterson, D. M., & Origlia, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165624 · Cited by 241
“Indeed, the activation of p38 MAPK has been verified in the brain during the early stages of AD, both clinically [6,66] and in mouse models [11,62,67,68].”
BackgroundAlzheimer neurofibrillary degeneration: significance, etiopathogenesis, therapeutics and prevention
Iqbal, K., & Grundke‐Iqbal, I. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00225.x · Cited by 238
Self-citationDisruption of fast axonal transport is a pathogenic mechanism for intraneuronal amyloid beta
Pigino, G., Morfini, G., Atagi, Y., Deshpande, A., Yu, C., Jungbauer, L., LaDu, M., Busciglio, J., & Brady, S. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0901229106 · Cited by 227
“A variety of kinases have been found to affect FAT in axoplasm (28), and multiple kinase activities are elevated in AD (GSK, JNK, CK2).”
BackgroundInfluentialMunoz, L., Ranaivo, H. R., Roy, S. M., Hu, W., Craft, J. M., McNamara, L. K., Chico, L. W., Van Eldik, L. J., & Watterson, D. M. (2007) · Journal of Neuroinflammation · doi:10.1186/1742-2094-4-21 · Cited by 224
“The p38 MAPK signaling cascade is activated in AD as demonstrated by staining of AD brain tissue samples for phosphorylated (activated) p38 MAPK or upstream components of the pathway [19,41-46].”
Kanaan, N. M., Pigino, G. F., Brady, S. T., Lazarov, O., Binder, L. I., & Morfini, G. A. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2012.06.003 · Cited by 212
Role of p38/MAPKs in Alzheimer's Disease: Implications for Amyloid Beta Toxicity Targeted Therapy
Kheiri, G., Dolatshahi, M., Rahmani, F., & Rezaei, N. (2018) · Reviews in the Neurosciences · doi:10.1515/revneuro-2018-0008 · Cited by 211
Origlia, N., Righi, M., Capsoni, S., Cattaneo, A., Fang, F., Stern, D. M., Chen, J. X., Schmidt, A. M., Arancio, O., Yan, S. D., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.0204-08.2008 · Cited by 202
“The amplitude of the FPs was used as a measure of the evoked population excitatory current (Domenici et al., 1995; Pesavento et al., 2002).”
MethodCorreia, S. C., Santos, R. X., Carvalho, C., Cardoso, S., Candeias, E., Santos, M. S., Oliveira, C. R., & Moreira, P. I. (2012) · Brain Research · doi:10.1016/j.brainres.2011.12.063 · Cited by 195
Deregulated Cdk5 activity is involved in inducing Alzheimer's disease
Shukla, V., Skuntz, S., & Pant, H. C. (2012) · Archives of Medical Research · doi:10.1016/j.arcmed.2012.10.015 · Cited by 185
“435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514…”
Chronic oxidative stress causes increased tau phosphorylation in M17 neuroblastoma cells
Su, B., Wang, X., Lee, H.-G., Tabaton, M., Perry, G., Smith, M. A., & Zhu, X. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2009.11.010 · Cited by 179
Impaired insulin signalling and allostatic load in Alzheimer disease
De Felice, F. G., Gonçalves, R. A., & Ferreira, S. T. (2022) · Nature Reviews Neuroscience · doi:10.1038/s41583-022-00558-9 · Cited by 177
Role of protein kinase B in Alzheimer's neurofibrillary pathology
Pei, J.-J., Khatoon, S., An, W.-L., Nordlinder, M., Tanaka, T., Braak, H., Tsujio, I., Takeda, M., Alafuzoff, I., Winblad, B., et al. (2003) · Acta Neuropathologica · doi:10.1007/s00401-002-0657-y · Cited by 165
Self-citationRelationship Between Tau Pathology and Neuroinflammation in Alzheimer's Disease
Metcalfe, M. J., & Figueiredo‐Pereira, M. E. (2010) · Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20163 · Cited by 158
Bachstetter, A. D., & Eldik, L. J. V. (2010) · PubMed · Cited by 211
Role of TGFβ signaling in the pathogenesis of Alzheimer’s disease
von Bernhardi, R., Cornejo, F., Parada, G. E., & Eugenín, J. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00426 · Cited by 149
“MAPKs include extracellular signal-regulated protein kinases (ERKs) and stress activated protein kinases c-Jun NH2-terminal kinase (JNK) and P38.”
BackgroundInfluentialSevoflurane Induces Tau Phosphorylation and Glycogen Synthase Kinase 3β Activation in Young Mice
Tao, G., Zhang, J., Zhang, L., Dong, Y., Yu, B., Crosby, G. J., Culley, D. J., Zhang, Y., & Xie, Z. (2014) · Anesthesiology · doi:10.1097/aln.0000000000000278 · Cited by 151
Pei, J.-J., Gong, C., An, W., Winblad, B. G., Cowburn, R. F., Grundke, I., & Iqbal, K. (2003) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63445-1 · Cited by 156
Self-citationEldik, L. J. V., Thompson, W. L., Ranaivo, H. R., Behanna, H. A., & Watterson, D. M. (2007) · International review of neurobiology · doi:10.1016/s0074-7742(07)82015-0 · Cited by 149
Role of Hydrogen Peroxide in the Aetiology of Alzheimer??s Disease: Implications for Treatment
Milton, N. G. N. (2004) · Drugs & Aging · doi:10.2165/00002512-200421020-00002 · Cited by 158
The role of intracellular zinc release in aging, oxidative stress, and Alzheimer’s disease
McCord, M. C., & Aizenman, E. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00077 · Cited by 136
“Namely, numerous studies report increased phosphorylation of p38 in AD brains (Hensley et al., 1999; Zhu et al., 2000, 2001; Pei et al., 2001; Sun et al., 2003), which is also required for zincmediated neuronal apoptosis (McLaughlin et al., 2001).”
BackgroundMolecular mechanisms linking amyloid β toxicity and Tau hyperphosphorylation in Alzheimer׳s disease
Lloret, A., Fuchsberger, T., Giraldo, E., & Viña, J. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.02.028 · Cited by 135
Wang, J.-Z., Tung, Y. C., Wang, Y., Li, X. T., Iqbal, K., & Grundke-Iqbal, I. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)02944-1 · Cited by 130
Self-citationDown-regulation of WW Domain-containing Oxidoreductase Induces Tau Phosphorylation in Vitro
Sze, C.-I., Su, M., Pugazhenthi, S., Jambal, P., Hsu, L.-J., Heath, J., Schultz, L., & Chang, N.-S. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m401399200 · Cited by 130
Post-translational modifications: Regulators of neurodegenerative proteinopathies
Gupta, R. V., Sahu, M., Srivastava, D., Tiwari, S., Ambasta, R. K., & Kumar, P. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101336 · Cited by 133
P70 S6 kinase mediates tau phosphorylation and synthesis
Pei, J.-J., An, W.-L., Zhou, X.-W., Nishimura, T., Norberg, J., Benedikz, E., Götz, J., & Winblad, B. (2006) · FEBS Letters · doi:10.1016/j.febslet.2005.11.059 · Cited by 119
Self-citationAre there roles for brain cell senescence in aging and neurodegenerative disorders?
Tan, F. C. C., Hutchison, E. R., Eitan, E., & Mattson, M. P. (2014) · Biogerontology · doi:10.1007/s10522-014-9532-1 · Cited by 116
“Activity of p38MAPK is increased in neurons of AD patients with neurofibrillary tangles and precedes Ab plaques in mouse models of AD (Pei et al. 2001; Savage et al. 2002; Sun et al. 2003).”
p38 MAP Kinase Inhibitors as Potential Therapeutic Drugs for Neural Diseases
Yasuda, S., Sugiura, H., Tanaka, H., Takigami, S., & Yamagata, K. (2011) · Central Nervous System Agents in Medicinal Chemistry · doi:10.2174/187152411794961040 · Cited by 115
Anesthesia Induces Phosphorylation of Tau
Run, X., Liang, Z., Zhang, L., Iqbal, K., Grundke-Iqbal, I., & Gong, C.-X. (2009) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-1003 · Cited by 114
“Both JNK and MAPK have been implicated in hyperphosphorylation of tau and the pathogenesis of AD [21–24].”
Self-citationKamat, P. K., Rai, S., Swarnkar, S., Shukla, R., & Nath, C. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8699-4 · Cited by 124
Origlia, N., Bonadonna, C., Rosellini, A., Leznik, E., Arancio, O., Yan, S. S., & Domenici, L. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.2127-10.2010 · Cited by 111
“Stress-related protein kinases, such as JNK and p38 MAPK, are activated in several pathologic processes, including AD neurodegeneration and A cytotoxicity (Pei et al., 2001; Troy et al., 2001; Zhu et al., 2005).”
BackgroundInflammation and Alzheimer’s Disease: Mechanisms and Therapeutic Implications by Natural Products
Rather, M. A., Khan, A., Alshahrani, S., Rashid, H., Qadri, M. M., Rashid, S., Alsaffar, R. M., Kamal, M. A., & Rehman, M. U. (2021) · Mediators of Inflammation · doi:10.1155/2021/9982954 · Cited by 120
“In AD, postmortem studies have reported that exaggerated immunoreactivity of phospho-p38 MAPK was linked with A β plaques and neuro fi brillary tangle-oriented neurons, and it was further observed in patients with AD that activation of p38 MAPK begins at the early stage of the disease [85, 86].”
Role of dietary fatty acids in microglial polarization in Alzheimer’s disease
Desale, S. E., & Chinnathambi, S. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01742-3 · Cited by 106
An, W., Bjorkdahl, C., Liu, R., Cowburn, R. F., Winblad, B., & Pei, J. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02948.x · Cited by 106
Self-citationThe p38 MAP kinase signaling pathway in Alzheimer's disease
Johnson, G. (2003) · Experimental Neurology · doi:10.1016/s0014-4886(03)00268-1 · Cited by 106
Xing, B., Bachstetter, A. D., & Van Eldik, L. J. (2011) · Molecular Neurodegeneration · doi:10.1186/1750-1326-6-84 · Cited by 101
“The p38 MAPK pathway has been suggested to play a central role in various pathological CNS conditions including cerebral ischemia [15,16] and Parkinson’s disease [17-19], as well as in AD [20,21], where postmortem studies find p38 MAPK activation occurs at the very early stage of the disease [20,22].”
Axonal Stress Kinase Activation and Tau Misbehavior Induced by Kinesin-1 Transport Defects
Falzone, T. L., Stokin, G. B., Lillo, C., Rodrigues, E. M., Westerman, E. L., Williams, D. S., & Goldstein, L. S. B. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.0780-09.2009 · Cited by 101
“5, available at www. jneurosci.org as supplemental material); consistent with previous observations in early stages of neurofibrillary pathology formation (Pei et al., 2001; Lagalwar et al., 2006).”
BackgroundResultAlpha7 nicotinic acetylcholine receptor: A link between inflammation and neurodegeneration
Conejero‐Goldberg, C., Davies, P., & Ulloa, L. (2007) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2007.10.007 · Cited by 112
“P38MAPK expression appears restricted to neurons and glial cells containing hyperphosphorylated tau, as well as dystrophic neurites of senile plaques in AD (Pei et al., 2001).”
BackgroundThe Proteasome and Oxidative Stress in Alzheimer's Disease
Bonet-Costa, V., Pomatto, L. C.-D., & Davies, K. J. A. (2016) · Antioxidants & Redox Signaling · doi:10.1089/ars.2016.6802 · Cited by 99
“Increased levels of unbound Tau (143), or declines in kinase activity (110, 121), may increase the likelihood of Tau misfolding.”
Lachén‐Montes, M., González-Morales, A., Zelaya, M. V., Pérez‐Valderrama, E., Ausín, K., Ferrer, I., Fernández‐Irigoyen, J., & Santamaría, E. (2017) · Scientific Reports · doi:10.1038/s41598-017-09481-x · Cited by 107
Signal Transduction Cascades Associated with Oxidative Stress in Alzheimer's Disease
Petersen, R. B., Nunomura, A., Lee, H.-G., Casadesus, G., Perry, G., Smith, M. A., & Zhu, X. (2007) · Journal of Alzheimer's Disease · doi:10.3233/jad-2007-11202 · Cited by 97
“An increase in activation of MKK6 and p38 and their association with neurofibrillary pathology is also well documented in AD and other tauopathies [4, 20,24,25,61,62,108,110].”
Gourmaud, S., Paquet, C., Dumurgier, J., Pace, C., Bouras, C., Gray, F., Laplanche, J.-L., Meurs, E. F., Mouton-Liger, F., & Hugon, J. (2015) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.140062 · Cited by 96
Phosphorylated Tau: Toxic, Protective, or None of the Above
Castellani, R. J., Nunomura, A., Lee, H.-G., Perry, G., & Smith, M. A. (2008) · Journal of Alzheimer's Disease · doi:10.3233/jad-2008-14404 · Cited by 91
“An increase in activation of MKK6 and p38 and their association with neurofibrillary pathology is also well documented in AD and other tauopathies [1,11,13,14,32,33,58,60].”
Vingtdeux, V., Hamdane, M., Gompel, M., Bégard, S., Drobecq, H., Ghestem, A., Grosjean, M.-E., Kostanjevecki, V., Grognet, P., Vanmechelen, E., et al. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.05.004 · Cited by 88
“The intraneuronal accumulation of activated JNK was also suggested to precede the deposition of amyloid in the extracellular space (Pei et al., 2001).”
BackgroundPuig, B., Gómez‐Isla, T., Ribé, E., Cuadrado, M., Torrejón‐Escribano, B., Dalfó, E., & Ferrer, I. (2004) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2004.00569.x · Cited by 86
Phosphorylated eukaryotic translation factor 4E is elevated in Alzheimer brain
Li, X., An, W.-L., Alafuzoff, I., Soininen, H., Winblad, B., & Pei, J.-J. (2004) · NeuroReport · doi:10.1097/00001756-200410050-00019 · Cited by 84
Self-citationNeuroprotective strategies in Alzheimer’s disease
Longo, F. M., & Massa, S. M. (2004) · NeuroRx · doi:10.1602/neurorx.1.1.117 · Cited by 83
“Immunostaining reveals JNK activation in degenerating neurons in AD brain,(21,22) including in association with intraneuronal A accumulation and in association with tangle-like inclusions in entorhinal cortex before A deposition.(23,24) Interestingly, evidence suggests that JNK activation also contributes to tau phosp…”
BackgroundZeitlin, R., Patel, S., Burgess, S., Arendash, G. W., & Echeverría, V. (2011) · Brain Research · doi:10.1016/j.brainres.2011.08.036 · Cited by 90
Small Molecule JNK (c-Jun N-Terminal Kinase) Inhibitors
Siddiqui, M. A., & Reddy, P. A. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm9003279 · Cited by 76
D’Mello, S. R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115911 · Cited by 85
Costantini, C., Rossi, F., Formaggio, E., Bernardoni, R., Cecconi, D., & Bianca, V. D. (2005) · Journal of Molecular Neuroscience · doi:10.1385/jmn:25:2:141 · Cited by 74
“Finally, mitogen-activated protein kinase (MAPK) phosphorylation has been documented in neurons from both AD patients and animal models of AD (Pei et al., 2001; Savage et al., 2002; Zhu et al., 2003), and in vitro studies have shown that Aβ-induced cell death is associated with an increase in MAPK…”
BackgroundCdk5 is a major regulator of p38 cascade: relevance to neurotoxicity in Alzheimer’s disease
Chang, K., De Pablo, Y., Lee, H., Lee, H., Smith, M. A., & Shah, K. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06687.x · Cited by 74
MAPK, β-amyloid and synaptic dysfunction: the role of RAGE
Origlia, N., Arancio, O., Domenici, L., & Yan, S. S. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.107 · Cited by 70
Zhou, X.-W., Li, X., Bjorkdahl, C., Sjogren, M. J., Alafuzoff, I., Soininen, H., Grundke-Iqbal, I., Iqbal, K., Winblad, B., & Pei, J.-J. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.01.006 · Cited by 66
Self-citationRaikwar, S. P., Thangavel, R., Dubova, I., Selvakumar, G. P., Ahmed, M. E., Kempuraj, D., Zaheer, S. A., Iyer, S. S., & Zaheer, A. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1068-y · Cited by 73
Levin‐Salomon, V., Kogan, K., Ahn, N. G., Livnah, O., & Engelberg, D. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m806443200 · Cited by 65
Falzone, T. L., Gunawardena, S., McCleary, D., Reis, G. F., & Goldstein, L. S. B. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq363 · Cited by 64
Formation of Phospho-SAPK/JNK Granules in the Hippocampus Is an Early Event in Alzheimer Disease
Lagalwar, S., Guillozet-Bongaarts, A. L., Berry, R. W., & Binder, L. I. (2006) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/01.jnen.0000229236.98124.d8 · Cited by 64
Pearson, A. G., Curtis, M. A., Waldvogel, H. J., Faull, R. L. M., & Dragunow, M. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2005.02.029 · Cited by 68
Sahara, N., Murayama, M., Lee, B., Park, J., Lagalwar, S., Binder, L. I., & Takashima, A. (2008) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06258.x · Cited by 62
“Several immunohistochemical studies have demonstrated that phospho-JNK co-localizes with pathological tau inclusions (Pei et al., 2001; Ferrer et al., 2003; Lagalwar et al., 2006).”
BackgroundAshabi, G., Ramin, M., Azizi, P., Taslimi, Z., Alamdary, S. Z., Haghparast, A., Ansari, N., Motamedi, F., & Khodagholi, F. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.04.006 · Cited by 65
Potential of GPCRs to modulate MAPK and mTOR pathways in Alzheimer’s disease
Franco, R., Martínez‐Pinilla, E., Navarro, G., & Zamarbide, M. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.01.004 · Cited by 65
Kuo, L.-H., Hu, M.-K., Hsu, W.-M., Tung, Y.-T., Wang, B.-J., Tsai, W.-W., Yen, C.-T., & Liao, Y.-F. (2008) · Molecular Biology of the Cell · doi:10.1091/mbc.e07-09-0987 · Cited by 55
“It is thus conceivable that all three major JNK isoforms (JNK1, JNK2, and JNK3) could be affected in AD (Shoji et al., 2000; Ferrer et al., 2001; Pei et al., 2001; Zhu et al., 2001).”
BackgroundKim, M., Lee, J.-H., Jung, K., Kim, M., Park, Y.-J., Ahn, H., Kwon, Y. H., & Hah, J. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.02.021 · Cited by 54
Ferrer, I. (2004) · Neurotoxicity Research · doi:10.1007/bf03033283 · Cited by 57
“Immunohistochemical studies have shown increased expression of MAPK/ERK, SAPK/JNK, p38 and PKA, co-localizing hyper-phosphorylated tau deposits and NFTs, in individual neurons in AD (Hensley et al., 1999; Knowles et al., 1999; Perry et al., 1999; Zhu et al., 2000; 2001b; 2002; Atzori et al., 2001; Ferrer et al., 2001a…”
BackgroundActivated c-Jun is present in neurofibrillary tangles in Alzheimer's disease brains
Pearson, A. G., Byrne, U. T. E., MacGibbon, G. A., Faull, R. L. M., & Dragunow, M. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2006.01.031 · Cited by 62
Alberghina, L., & Colangelo, A. M. (2006) · BMC Neuroscience · doi:10.1186/1471-2202-7-s1-s2 · Cited by 55
“Active forms of JNK and p38 kinase have been found in hippocampal and cortical neurons of AD brains, suggesting their potential implication in hyperphosphorylation of tau and NFT formation [176].”
BackgroundAshabi, G., Alamdary, S. Z., Ramin, M., & Khodagholi, F. (2012) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12000 · Cited by 52
c-Jun N-Terminal Kinase Inhibitors as Potential Leads for New Therapeutics for Alzheimer’s Diseases
Rehfeldt, S. C. H., Majolo, F., Goettert, M. I., & Laufer, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249677 · Cited by 52
“As previously mentioned, the CMGC kinase group shares many similarities within their kinase domain, especially at the catalytic subunit, which catalyzes the transfer of the γ-phosphate from ATP to serine or threonine residues of protein substrates [35].”
BackgroundD'Abramo, C., Ricciarelli, R., Pronzato, M. A., & Davies, P. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03931.x · Cited by 45
Mechanistic complexities of bone loss in Alzheimer’s disease: a review
Frame, G., Bretland, K. A., & Dengler-Crish, C. M. (2020) · Connective Tissue Research · doi:10.1080/03008207.2019.1624734 · Cited by 44
Cyclin dependent kinase 5: A novel avenue for Alzheimer’s disease
Bhounsule, A. S., Bhatt, L. K., Prabhavalkar, K. S., & Oza, M. J. (2017) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2017.05.006 · Cited by 45
P38 Activation Mediates Amyloid-β Cytotoxicity
Zhu, X., Mei, M. G., Lee, H., Wang, Y., Han, J., Perry, G. L., & Smith, M. A. (2005) · Neurochemical Research · doi:10.1007/s11064-005-6872-x · Cited by 46
The p38α mitogen-activated protein kinase as a central nervous system drug discovery target
Borders, A. S., de Almeida, L., Van Eldik, L. J., & Watterson, D. M. (2008) · BMC Neuroscience · doi:10.1186/1471-2202-9-s2-s12 · Cited by 43
Yu, X., Wang, L., Ma, L., You, R., Cui, R., Ji, D., Wu, Y., Zhang, C., Yang, Z., & Ji, H. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2012.02.014 · Cited by 46
“Accumulating evidence indicates that three of the MAPK pathways, namely p38, c-Jun N-terminal kinase (JNK) and extracellular-regulated kinase 1/2 (ERK1/2), could play multiple roles in AD (Matsuzawa and Ichijo, 2008; Pei et al., 2001; Zhu et al., 2000).”
Developing pharmacological therapies for Alzheimer disease
Iqbal, K., & Grundke, I. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-7221-9 · Cited by 46
Self-citationMorillo, S. M., Abanto, E. P., Román, M. J., & Frade, J. M. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.00239-12 · Cited by 44
“Indeed, the expression of proNGF (64), p75 (32), active p38 (63, 69), E2F4 (50), and the type II MAGE protein Necdin (57) has been described in neurons from normal and Alzheimer’s diseaseaffected brains.”
BackgroundEdbauer, D., Cheng, D., Batterton, M. N., Wang, C.-F., Duong, D. M., Yaffe, M. B., Peng, J., & Sheng, M. (2008) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m800233-mcp200 · Cited by 47
Molecular Mechanisms of Cellular Senescence in Neurodegenerative Diseases
Lee, H.-J., Yoon, Y.-S., & Lee, S.-J. (2023) · Journal of Molecular Biology · doi:10.1016/j.jmb.2023.168114 · Cited by 36
Metadata
- Authors
- Pei, J.-J., Braak, E., Braak, H., Grundke-Iqbal, I., Iqbal, K., Winblad, B., & Cowburn, R. F.
- Affiliations
- Karolinska Institutet (SE)
- Goethe University Frankfurt (DE)
- NYS Institute for Basic Research in Developmental Disabilities, Staten Island, NY, USA
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2001-03-05
- Volume
- 3
- Issue
- 1
- Pages
- 41-48
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W86871181
- Cited by
- 165
- References
- 26
- Citations by year
- 2026: 5 · 2025: 4 · 2024: 2 · 2023: 4 · 2022: 6 · 2021: 8 · 2020: 6 · 2019: 3 · 2018: 4 · 2017: 8 · 2016: 2 · 2015: 7 · 2014: 6 · 2013: 6 · 2012: 7
- FWCI
- 4.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Alzheimer s Disease (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Deutsche Forschungsgemeinschaft
- Alzheimerfonden
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, c-Jun kinase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.